These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 34558337)

  • 21. Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients With Impaired Liver Function: A Retrospective Cohort Study.
    Wang CL; Wu VC; Kuo CF; Chu PH; Tseng HJ; Wen MS; Chang SH
    J Am Heart Assoc; 2018 Aug; 7(15):e009263. PubMed ID: 30371232
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vitamin K and non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation in real-life.
    Giustozzi M; Vedovati MC; Verdecchia P; Pierpaoli L; Verso M; Conti S; Cianella F; Marchesini E; Filippucci E; Agnelli G; Becattini C
    Eur J Intern Med; 2016 Sep; 33():42-6. PubMed ID: 27394924
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention for Newly Diagnosed and Treatment-Naive Atrial Fibrillation Patients: An Update Using 2013-2014 Data.
    Brown JD; Shewale AR; Talbert JC
    J Manag Care Spec Pharm; 2017 Sep; 23(9):958-967. PubMed ID: 28854077
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparing the Effectiveness and Safety of Nonvitamin K Antagonist Oral Anticoagulants and Warfarin in Elderly Asian Patients With Atrial Fibrillation: A Nationwide Cohort Study.
    Chao TF; Chiang CE; Liao JN; Chen TJ; Lip GYH; Chen SA
    Chest; 2020 May; 157(5):1266-1277. PubMed ID: 31809694
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of patient selection in clinical trials: application of ROCKET AF and ARISTOTLE criteria in GARFIELD-AF.
    Himmelreich JCL; Virdone S; Camm J; Pieper K; Harskamp RE; Oto A; Jacobson BF; Sawhney JPS; Lim TW; Gibbs H; Goto S; Haas S; Fox KAA; Jansky P; Verheugt F; Kakkar AK;
    Open Heart; 2024 Jul; 11(2):. PubMed ID: 38955399
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Label Adherence for Non-Vitamin K Antagonist Oral Anticoagulants in a Prospective Cohort of Asian Patients with Atrial Fibrillation.
    Lee SR; Lee YS; Park JS; Cha MJ; Kim TH; Park J; Park JK; Lee JM; Kang KW; Shim J; Uhm JS; Kim J; Kim C; Kim JB; Park HW; Joung B; Choi EK
    Yonsei Med J; 2019 Mar; 60(3):277-284. PubMed ID: 30799590
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK setting.
    Zheng Y; Sorensen SV; Gonschior AK; Noack H; Heinrich-Nols J; Sunderland T; Kansal AR
    Clin Ther; 2014 Dec; 36(12):2015-2028.e2. PubMed ID: 25438722
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative clinical outcomes between direct oral anticoagulants and warfarin among elderly patients with non-valvular atrial fibrillation in the CMS medicare population.
    Amin A; Keshishian A; Dina O; Dhamane A; Nadkarni A; Carda E; Russ C; Rosenblatt L; Mardekian J; Yuce H; Baker CL
    J Thromb Thrombolysis; 2019 Aug; 48(2):240-249. PubMed ID: 30924051
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oral anticoagulant persistence in patients with non-valvular atrial fibrillation: A cohort study using primary care data in Germany.
    Collings SL; Lefèvre C; Johnson ME; Evans D; Hack G; Stynes G; Maguire A
    PLoS One; 2017; 12(10):e0185642. PubMed ID: 29016695
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Non-vitamin K antagonist oral anticoagulants versus warfarin in AF patients ≥ 85 years.
    Tsai CT; Liao JN; Chen SJ; Jiang YR; Chen TJ; Chao TF
    Eur J Clin Invest; 2021 Jun; 51(6):e13488. PubMed ID: 33420738
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Appropriateness of initial dose of non-vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation in the UK.
    García Rodríguez LA; Martín-Pérez M; Vora P; Roberts L; Balabanova Y; Brobert G; Fatoba S; Suzart-Woischnik K; Schaefer B; Ruigomez A
    BMJ Open; 2019 Sep; 9(9):e031341. PubMed ID: 31542760
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Trends in the prescription of novel oral anticoagulants in UK primary care.
    Loo SY; Dell'Aniello S; Huiart L; Renoux C
    Br J Clin Pharmacol; 2017 Sep; 83(9):2096-2106. PubMed ID: 28390065
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relevance of P-glycoprotein in stroke prevention with dabigatran, rivaroxaban, and apixaban.
    Stöllberger C; Finsterer J
    Herz; 2015 Apr; 40 Suppl 2():140-5. PubMed ID: 25616425
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative effectiveness of factor Xa non-vitamin K antagonist oral anticoagulants versus phenprocoumon in patients with non-valvular atrial fibrillation.
    Kreutz R; Kloss S; Enders D; Abdelgawwad K; Häckl D; Schmedt N; Bonnemeier H
    Int J Cardiol; 2024 Jun; 404():131894. PubMed ID: 38437952
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Cancer and Atrial Fibrillation: A Systematic Review and Meta-Analysis.
    Deng Y; Tong Y; Deng Y; Zou L; Li S; Chen H
    J Am Heart Assoc; 2019 Jul; 8(14):e012540. PubMed ID: 31310583
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulant and Warfarin in Cirrhotic Patients With Nonvalvular Atrial Fibrillation.
    Lee HF; Chan YH; Chang SH; Tu HT; Chen SW; Yeh YH; Wu LS; Kuo CF; Kuo CT; See LC
    J Am Heart Assoc; 2019 Mar; 8(5):e011112. PubMed ID: 30834802
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in octogenarian patients with non-valvular atrial fibrillation.
    Kim HM; Choi EK; Park CS; Cha MJ; Lee SY; Kwon JM; Oh S
    PLoS One; 2019; 14(3):e0211766. PubMed ID: 30845196
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.
    Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH
    Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Estimated Effectiveness and Safety of Nonvitamin K Antagonist Oral Anticoagulants Compared With Optimally Acenocoumarol Anticoagulated "Real-World" in Patients With Atrial Fibrillation.
    Esteve-Pastor MA; Rivera-Caravaca JM; Roldán V; Orenes-Piñero E; Romiti GF; Romanazzi I; Bai Y; Carmo J; Proietti M; Marín F; Lip GYH
    Am J Cardiol; 2018 Sep; 122(5):785-792. PubMed ID: 30049460
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dabigatran, rivaroxaban and apixaban vs. high TTR warfarin in atrial fibrillation.
    Själander S; Sjögren V; Renlund H; Norrving B; Själander A
    Thromb Res; 2018 Jul; 167():113-118. PubMed ID: 29803981
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.